Customized Lentiviral Vectors for Cell Therapies
Accelerate your therapy from clinical trial to market

Vector Design
We provide tailored vector design services to meet the unique needs of researchers in gene-modified cell therapy. Our experienced team of advisors can help you create customized lentiviral vectors, combining efficiency, safety, and compliance with regulatory standards. By partnering with BioViros, researchers can accelerate their projects and maximize therapeutic success through our expert vector design solutions.

Pre-Clinical Manufacturing
At BioViros we excel in small-scale R&D manufacturing of lentiviral vectors using suspension cell cultures. This approach enables rapid, cost-effective vector production while maintaining high quality and yield. By utilizing suspension cells, we facilitate a seamless transition from early-stage research to large-scale manufacturing, ensuring that our clients' cell and gene therapy projects progress smoothly and efficiently.

Clinical-grade manufacturing
Our strategic partnerships for large-scale, GMP-compliant manufacturing of lentiviral vectors allow you access to Phase II and III scale production to ensure you pathway to market is uninterrupted by supply shortage. By implementing a robust process validation plan to ensure consistency and reproducibility we are continuously improving the manufacturing process to serve our clients.
Discovery and Pre-clinical research starts with a great vector design to ensure maximum cell potency and patient safety.
Depending on stage of your clinical trial, you need a GMP-like or cGMP grade viral vector to induce immune cells.
Seamless scale-up and GMP production with our strategic partners supports you through Phase 2 and Phase 3 trials.
Our strategic partnerships allow you to use end-to-end solution, from vector design and GMP plasmid production, to GMP CAR-T cell manufacturing and clinical trial consultation.
See what is new in our industry, learn more about the upcoming products and events.

BioViros @ Robotics & Biotechnology | 11 May 2023
Networking

News - NBR | February 2023
Article

News - #nzentrepreneur | November 2022
Article

News - EINPRESSWIRE | March 2023
Article